Benzinga

Benzinga

Benzinga

venerdì, settembre 04

Vertex Pharmaceuticals Inc

VRTXNASDAQ
Trade with Public
Trade with Public
$546.12
-11.84-2.12%
In chiusura: Sep 4, 5:00 PM EST
$546.39
0.270.05%
Post-mercato: 4:20 PM EST
Fusioni e acquisizioni: Crinetics Pharmaceuticals (CRNX) was acquired by Vertex Pharmaceuticals (VRTX) on Tuesday, September 1, 2026 for $10B paid in cash
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Vertex Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vertex Pharmaceuticals (VRTX).

Price Target Range — 7 Quarters

Analyst Consensus — 27 Analysts

21Buy
5Hold
1Sell
Consensus RatingBuy# Analysts27Avg. Consensus PT$542Upside to Avg. PT-0.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026Morgan StanleyTerence FlynnReinstatesOverweight$665
Aug 5, 2026Truist SecuritiesDanielle BrillPT RaiseBuy$560→$565
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.
Benzinga Newsdesk

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550

TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved